For the first time since Nov. 7, Saskatchewan is reporting fewer than 1,000 active cases of COVID-19.

There were 171 recoveries and 57 new cases reported today bringing the total active number of cases to 938.

72 of the active cases in the province are located in the sub-region 'south-central 2' which is made up of Moose Jaw and the surrounding area.

There was one new death reported, a person in their 50s from the Central West Zone.

There are 109 people are in hospital with 20 in intensive care.

Of the new cases, one is here in the South Central  Zone, 21 are in Saskatoon, and 12 are in Regina. 

Vaccines Reported

An additional 12,528 doses of COVID-19 vaccine have been given in Saskatchewan, bringing the total number of vaccines administered in the province to 828,652. 

The 12,528 doses of COVID-19 vaccine reported today were administered to residents living in the following zones: Far North West, 225; Far North Central, 2; Far North East, 200; North West, 407; North Central, 518; North East, 746; Saskatoon, 2,894; Central West, 338; Central East, 790; Regina, 3,624; South West, 489; South Central, 833; and South East, 1,247.  There were 215 doses administered with zone of residence pending.

Seventy-eight per cent of those over the age of 40 have received their first dose.  Seventy-three per cent of those 30+ have received their first dose.  Sixty-eight per cent of those 18+ have received their first dose, while sixty-five per cent of those 12+ have also received their first dose.

Eligibility for Second Dose Expands Thursday

All residents 12+ can receive their first dose.  Beginning June 10, second dose vaccinations will be open to include residents 55+ or anyone who received their first dose on or before April 7.  Individuals diagnosed with or being treated for cancer and those who have received solid organ transplants will receive a letter of eligibility in the mail that will allow them priority access to a second dose. 

Eligibility to book for second doses is based on age or date of first dose.  Residents who meet at least one of these criteria are eligible for their second dose.  The following table is a tentative guideline for those who received Pfizer or Moderna for their first dose; timelines may change due to vaccine availability.